Therapeutic Horizons: Gut Microbiome, Neuroinflammation, and Epigenetics in Neuropsychiatric Disorders
Cells · 04.07.2025 · 14 (13) · 1027
DOI: 10.3390/cells14131027 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 04.07.2025. Verfasst von Shabnam Nohesara und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine (Biomedical Genetics), Boston University Chobanian & Avedisian School of Medicine, Boston, MA 02118, USA. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Epigenesis, Genetic, Mental Disorders, Neuroinflammatory Diseases. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 204 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Neuroinflammation is a hallmark of many neuropsychiatric disorders (NPD), which are among the leading causes of disability worldwide. Emerging evidence highlights the significant role of the gut microbiota (GM)–immune system–brain axis in neuroinflammation and the pathogenesis of NPD, primarily through epigenetic mechanisms. Gut microbes and their metabolites influence immune cell activity and brain function, thereby contributing to neuroinflammation and the development and progression of NPD. The enteric nervous system, the autonomic nervous system, neuroendocrine signaling, and the immune system all participate in bidirectional communication between the gut and the brain. Importantly, the interaction of each of these systems with the GM influences epigenetic pathways. Here, we first explore the intricate relationship among intestinal microbes, microbial metabolites, and immune cell activity, with a focus on epigenetic mechanisms involved in NPD pathogenesis. Next, we provide background information on the association between inflammation and epigenetic aberrations in the context of NPD. Additionally, we review emerging therapeutic strategies—such as prebiotics, probiotics, methyl-rich diets, ketogenic diet, and medications—that may modulate the GM–immune system–brain axis via epigenetic regulation for the prevention or treatment of NPD. Finally, we discuss the challenges and future directions in investigating the critical role of this axis in mental health.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine (Biomedical Genetics), Boston University Chobanian & Avedisian School of Medicine, Boston, MA 02118, USA.
- Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA.
- Mental Health Research Center, Psychosocial Health Research Institute, Iran University of Medical Sciences, Tehran 14535, Iran.
- Department of Pathology & Laboratory Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, MA 02118, USA.
ORCID-Profile: Shabnam Nohesara, Hamid Mostafavi Abdolmaleky, Sam Thiagalingam
Zitieren
APA
Nohesara, S., Mostafavi Abdolmaleky, H., Pirani, A., & Thiagalingam, S. (2025). Therapeutic Horizons: Gut Microbiome, Neuroinflammation, and Epigenetics in Neuropsychiatric Disorders. Cells, 14(13), 1027. https://doi.org/10.3390/cells14131027
Vancouver
Nohesara S, Mostafavi Abdolmaleky H, Pirani A, Thiagalingam S. Therapeutic Horizons: Gut Microbiome, Neuroinflammation, and Epigenetics in Neuropsychiatric Disorders. Cells. 2025;14(13):1027. doi:10.3390/cells14131027
BibTeX
@article{Nohesara2025,
author = {Nohesara, Shabnam and Mostafavi Abdolmaleky, Hamid and Pirani, Ahmad and Thiagalingam, Sam},
title = {Therapeutic Horizons: Gut Microbiome, Neuroinflammation, and Epigenetics in Neuropsychiatric Disorders},
journal = {Cells},
year = {2025},
volume = {14},
number = {13},
pages = {1027},
doi = {10.3390/cells14131027}
}
EUVIMED